GLP-1 Medications: What You Need to Know

Key Takeaways

• GLP-1 receptor agonists have been shown in a network meta-analysis to produce meaningful reductions in body weight compared with placebo and some other weight-loss drugs (PMID 42419792).
• A multicenter U.S. cohort study found tirzepatide was associated with a reduced risk of pulmonary embolism and deep vein thrombosis compared with certain other medications (PMID 42460324).
• Research from the CRAVE study suggests GLP-1 therapy is linked to changes in food cravings and dietary quality, not just calorie restriction (PMID 42440974).
• Genetic differences in GLP-1 and GIP receptors may one day help personalize which incretin therapy works best for a given individual (PMID 42487666).
• Compounded GLP-1 products surged after drug shortages, but their quality, dosing accuracy, and safety oversight differ from FDA-approved branded versions (PMID 42467450).

What Are GLP-1 Medications and How Do They Work?

GLP-1 medications are a class of drugs that mimic a natural gut hormone to help control blood sugar, reduce appetite, and support weight loss. They work by activating specific receptors in the body—think of a receptor as a lock and the medication as a key—triggering effects that change how your body handles food and hunger.

Here's what happens when you take a GLP-1 medication:

• They replicate a hormone your gut naturally produces. After you eat, your intestines release glucagon-like peptide-1 (GLP-1). This hormone signals your pancreas to release insulin (lowering blood sugar), tells your liver to slow glucose production, and sends fullness signals to your brain. GLP-1 medications extend these signals, as described in Research on incretin therapy personalization.

• They slow digestion. GLP-1 medications delay how quickly food moves from your stomach into your intestines, so you feel full sooner and stay full longer—naturally reducing food intake. **

• They reduce food cravings. The CRAVE study found that people using GLP-1 receptor agonists reported meaningful reductions in food cravings and shifts in dietary quality—not just eating less, but often choosing different foods.

• They support significant weight loss. A systematic review and network meta-analysis found GLP-1 medications among the most effective drug options for adults with overweight or obesity, producing greater weight reduction than many older treatments.

Common GLP-1 medications include semaglutide (Ozempic® and Wegovy®) and liraglutide (Saxenda®). A newer class called dual agonists—like tirzepatide (Mounjaro®, Zepbound®)—activates both GLP-1 and GIP, a second hormone receptor that may amplify effects, as noted in Research on incretin therapy.

For older adults: These medications' effects—including appetite suppression and slowed digestion—may require extra monitoring and dose adjustments, according to Research on GLP-1 use in older adults.

Understanding how these medications work provides a foundation for the rest of this guide—including how combining them with fasting and lifestyle changes can be a complementary approach.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or health program.

How Do GLP-1 Drugs Compare to Other Weight-Loss Options?

GLP-1 medications currently lead the pack among non-surgical weight-loss options, producing greater average body-weight reductions than older prescription drugs — though bariatric surgery still achieves the largest losses overall. Here's how the options stack up.

---

GLP-1 Drugs vs. Older Weight-Loss Medications

A large systematic review and network meta-analysis compared multiple weight-loss drugs head-to-head in adults with overweight or obesity. Newer GLP-1–based medicines (like semaglutide and tirzepatide) produced meaningfully greater weight loss than older options such as orlistat (a fat-blocking pill) or naltrexone-bupropion (a combination pill that affects appetite signals in the brain). The practical difference: losing 5–8% of body weight versus 15–20% or more.

• Older drugs work through a single mechanism — blocking fat absorption or dulling hunger signals — and produce more modest results on average.
• GLP-1 drugs slow stomach emptying, reduce appetite, and change how the brain responds to food cues, which is why they tend to outperform single-mechanism options.

---

GLP-1 Drugs vs. Bariatric Surgery

Surgery (such as gastric bypass or sleeve gastrectomy) still produces the largest and most durable weight losses. However, GLP-1 medications offer a non-surgical alternative with a distinct advantage: a multicenter U.S. cohort study found that tirzepatide was associated with reduced risk of serious blood clots (pulmonary embolism and deep vein thrombosis) — a finding not yet established for surgical approaches.

A separate cancer-risk comparison study examined GLP-1 drugs alongside bariatric surgery and other weight-loss medicines, noting that risk profiles differ across options — an important consideration when choosing a long-term strategy with your doctor.

---

How Lifestyle Change Fits In

GLP-1 drugs work best as part of a broader plan. Research from the CRAVE study found that people on GLP-1 therapy experienced real changes in food cravings and dietary quality — meaning the medication may actually make healthy eating and fasting easier to sustain, not just add on top of willpower.

---

Not medical advice. This content is for general informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare professional before starting, changing, or stopping any medication or diet program.

What Does Research Say About Their Risks and Benefits?

Research shows that GLP-1 medications carry meaningful, well-documented benefits — including weight loss, reduced appetite, and lower risk of certain serious conditions — alongside real risks that become especially important when combined with fasting. Here is what the current evidence says.

---

Benefits supported by Research

• Significant weight loss. A large systematic review and network meta-analysis found that GLP-1 receptor agonists produced meaningful reductions in body weight compared with placebo, making them among the most effective non-surgical options available for adults with overweight or obesity. (systematic review, BMJ)

• Reduced food cravings and improved diet quality. The CRAVE study found that people taking GLP-1 medications reported lower cravings for high-fat and sweet foods, and their overall diet quality improved during treatment. This benefit may work with structured fasting to support healthier eating patterns. (CRAVE study)

• Lower risk of dangerous blood clots. A large U.S. multicenter cohort study found that tirzepatide (a dual GLP-1/GIP receptor agonist) was associated with reduced risk of pulmonary embolism and deep vein thrombosis — serious conditions that obesity itself increases the risk of. (multicenter cohort study)

• Cancer risk appears reassuring so far. A comparative study found that GLP-1 receptor agonists were not associated with increased overall cancer risk when compared with bariatric surgery and other weight-loss drugs, though longer-term data are still needed. (cancer risk comparison study)

---

Risks to know — especially when fasting

• Muscle and bone loss in older adults. Research on older adults notes that GLP-1 medications can accelerate loss of muscle mass and bone density — a concern that fasting can compound if protein intake and resistance exercise are not carefully maintained. ** (older adults review)

• Response varies by individual. Emerging Research suggests that genetic differences in GLP-1 and GIP receptors may influence how well a person responds to incretin-based therapy, meaning results are not uniform across all users. ** (incretin therapy personalization study)

• Compounded versions carry additional unknowns. Studies have documented a significant market for compounded GLP-1 medications, which are not FDA-approved and may vary in dose and purity — an added variable when adjusting eating windows. (compounded GLP-1 market study)

---

**⚠️ Not medical advice. **** This section presents general Research findings for informational purposes only. It is not a substitute for personalized guidance from a licensed healthcare provider who knows your full medical history.

What Are Compounded GLP-1 Products and Are They Safe?

⚠️ Disclaimer: This content is for general informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Never start, stop, or change any medication or health regimen based on this guide alone.

---

Compounded GLP-1 products are custom-made versions mixed by specialty pharmacies. While they may appear convenient or affordable, they carry meaningful safety and quality risks that FDA-approved brand-name versions do not.

What "compounded" means

A compounded medication is mixed from scratch by a pharmacy—often to address supply shortages or offer lower prices. During recent semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, compounded versions proliferated. Research tracking the GLP-1 market in two high-demand U.S. states found that compounded products remained widely available even after official shortages ended, raising questions about their continued use — post-shortage compounded GLP-1 market study.

Key differences between compounded and brand-name GLP-1s

Why the safety gap matters

Compounded pharmacies are not required to prove their products perform identically to the original drug. Ingredients, concentrations, and sterility standards vary widely between compounders. This is especially important when using GLP-1s alongside fasting: incorrect dosing—too high or too low—can affect how you feel during fasting windows, muscle retention, and side effect management.

WhatResearchh shows

A study analyzing clinical notes found that compounding use is often underreported in standard prescription records, meaning your doctor may not know you're using a compounded version — clinical notes and compounding use study. This communication gap can affect your care.

What to do

• Tell your prescribing provider if you are using or considering a compounded GLP-1.
• Ask your pharmacy for a certificate of analysis (proof of independent testing for purity and potency).
• Understand that published safety data for semaglutide or tirzepatide comes from brand-name studies, not compounded formulas.

Have an honest conversation with your healthcare provider about which option is appropriate for your situation.

Who Should Be Extra Cautious About Using GLP-1 Medications?

Most people can use GLP-1 medications safely, but certain groups face higher risks and need closer medical supervision — especially when combining these drugs with fasting. If you fall into any of the categories below, it doesn't mean GLP-1 therapy is off the table; it means you need a deeper conversation with your doctor before starting. **

---

Older Adults (generally 65 and older)

Aging changes how the body processes medication and handles reduced calorie intake. According to a clinical review on GLP-1 use in older adults (source), this population faces higher risks of:

• Muscle loss (sarcopenia): GLP-1 medications significantly reduce appetite. Combined with fasting, older adults may not consume enough protein to maintain muscle mass.
• Malnutrition: Reduced hunger signals can mask genuine nutritional needs.
• Falls and fractures: Weight loss that includes muscle loss increases fall risk — a serious concern for older adults.
• Dehydration: Nausea and vomiting (common side effects) are more problematic when fluid reserves are already lower with age.

The same review notes that older adults may need individualized dosing, more frequent monitoring, and specific guidance on protein intake and resistance exercise to mitigate these risks.

---

People with a Personal or Family History of Certain Cancers

Research on GLP-1 medications and cancer risk continues to evolve. A large comparative study found that GLP-1 receptor agonists were associated with a reduced risk of several obesity-related cancers. However, the same study noted caution regarding thyroid cancer — specifically medullary thyroid carcinoma. People with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN2, a rare inherited hormonal disorder) are generally advised to avoid GLP-1 medications.

---

People with a History of Restrictive Eating or Low Body Weight

GLP-1 medications powerfully suppress appetite and alter food cravings. The CRAVE study documented significant reductions in dietary intake and changes in food preferences during treatment. For someone with a history of restrictive eating or who is already at low body weight, adding fasting could push calorie and nutrient intake to dangerous levels.

---

People Using Compounded or Unverified GLP-1 Products

Not all GLP-1 products come from licensed pharmacies with verified dosing. Research on compounded GLP-1 products found significant variability in the compounded market, raising concerns about dose accuracy and safety — risks that intensify when fasting further stresses the body.

---

⚠️ This content is for general informational purposes only and is not medical advice. It does not replace a consultation with a licensed healthcare provider. Always speak with your doctor before starting, changing, or stopping any medication or dietary practice.

Could Your Genes Affect How Well a GLP-1 Drug Works for You?

Yes, your genes can influence how well a GLP-1 medication works for you — though genetics is just one piece of a larger puzzle that also includes your diet, activity level, and other health factors. Research is still early, but the science points toward real, measurable differences in medication response based on genetic makeup.

---

What the Research shows

Scientists have identified variations in the genes that code for GLP-1 receptors — the docking sites on your cells where GLP-1 medications attach and function. These variations are called polymorphisms (small differences in your DNA sequence). According to a 2025 review on incretin therapy personalization, polymorphisms in the GLP-1 receptor gene (GLP1R) and the GIP receptor gene (GIPR) may influence how strongly a person responds to GLP-1 and dual GLP-1/GIP medications like tirzepatide.

Based on that same incretin personalization review, here's what this means in practice:

• Some gene variants are linked to better blood sugar control in response to GLP-1 therapy, while others are associated with a weaker glucose-lowering effect.
• Weight loss responses may vary depending on which receptor variants a person carries — meaning two people on the same dose of the same drug may lose meaningfully different amounts of weight.
• GIP receptor variants (relevant to tirzepatide, which targets both GLP-1 and GIP receptors) may separately affect medication efficacy.

---

What this means if you're combining GLP-1s with fasting

Genetics doesn't work in isolation. Even if you carry a variant that slightly reduces your medication response, lifestyle factors — including diet quality and fasting practice — still matter significantly. For example, the CRAVE study found that people on GLP-1 therapy showed meaningful improvements in food cravings and dietary quality, suggesting that behavioral and biological factors work together.

If you feel your medication isn't working as expected despite consistent fasting and healthy eating, genetics could be a contributing factor — and it's worth discussing with your prescribing clinician. Genetic testing for medication response (pharmacogenomics) is a growing field, though it is not yet standard practice for GLP-1 prescribing.

---

This content is for general informational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making changes to your medication or health plan.

FAQ

Are GLP-1 medications the same as weight-loss surgery?

No. A study comparing GLP-1 receptor agonists with bariatric surgery and other weight-loss drugs found differences in outcomes including cancer risk profiles, though both approaches are used for obesity management (PMID 42447648). Your healthcare provider can help you understand which option may be appropriate for your situation.

Do GLP-1 medications change what you want to eat?

Research from the CRAVE study suggests that people taking GLP-1 receptor agonists reported changes in food cravings and dietary quality alongside changes in body composition and overall dietary intake—suggesting the drugs may influence eating behavior beyond simply reducing appetite (PMID 42440974).

Is tirzepatide different from other GLP-1 medications?

Tirzepatide targets both GLP-1 and GIP receptors, making it a dual incretin agonist. A multicenter U.S. cohort study found it was associated with a lower risk of pulmonary embolism and deep vein thrombosis compared with some other agents. However, more Research is needed to confirm these findings (PMID 42460324).

What should older adults know before starting a GLP-1 medication?

A review on GLP-1 use in older adults highlighted special considerations such as the risk of muscle mass loss, fall risk, nutritional adequacy, and the importance of individualized dosing—making it especially important for older patients to work closely with their healthcare team (PMID 42423951).

Are compounded GLP-1 products a safe alternative to brand-name versions?

Research examining the post-shortage compounded GLP-1 market found that compounded products became widely available in states with high demand. Still, they are not FDA-approved and may vary in quality, concentration, and safety standards compared with regulated brand-name drugs (PMID 42467450). Always discuss medication sourcing with a licensed healthcare provider.

Could a GLP-1 medication affect cancer risk?

A study comparing GLP-1 receptor agonists with bariatric surgery and other weight-loss drugs examined cancer risk outcomes, noting differences across treatment types (PMID 42447648). The Research in this area is still evolving, and individuals with personal or family cancer histories should discuss this topic directly with their doctor.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs, and fasting is not right for everyone — talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.